Nguyen Nguyen Quach Chau
Nguyen Nguyen Quach Chau has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Hoang Kim Tu Trinh
Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
1 shared publication - Hoang Ngo Xuan
Pham Ngoc Thach University of Medicine, Ho Chi Minh, Viet Nam
1 shared publication - Vinh Ngo Minh
Biomedical Research Center, Pham Ngoc Thac University of Medicine, Ho Chi Minh City 700000, Vietnam
1 shared publication
Latest Publications
- Open Access
- 4 June 2024
- Published by Bentham Science Publishers Ltd. in The Open Dermatology Journal
- Vol. 18 (1)
Serum Visfatin Level in Psoriasis Patients: A Case-Control Study
Background: Adipokines play imperative roles in the pathogenesis of psoriasis. Among the adipokines, visfatin is attracting more attention in the clinical setting of dermatology. Objective: The study aims to evaluate the serum visfatin level in psoriasis patients compared to the non-psoriasis individuals. Material and Methods: This case-control study involved 40 psoriasis patients and 40 non-psoriasis individuals from January to October, 2023, at the Ho Chi Minh City (HCMC) Hospital of Dermato-Venereology. The diagnosis of psoriasis was based on clinical signs and symptoms. Visfatin level was spectrophotometrically measured using an Enzym-Linked Immunosorbent Assay (ELISA) kit. Afterward, data analysis was performed using SPSS version 25. Results: We recorded a significantly higher visfatin level in the psoriasis group than the controls (49.8 ± 26.04 versus 13.07 ±12.44, p-value <0.001). The cut-off threshold of visfatin level to differentiate psoriasis from non-psoriasis was 21.7 ng/ml with a sensitivity of 90% and a specificity of 85% (AUC = 0.929). We also found a positive correlation between visfatin level and Psoriasis Area and Severity Index (PASI) score (r = 0.704; p <0.001). Conclusion: Our study indicated the link between serum level of visfatin and psoriasis. Visfatin is a potential biomarker in diagnosing psoriasis and classifying the disease’s severity. In further cohort studies and clinical trials, the adipokine can be validated for its use in psoriasis.
- 4 June 2024
- Published by Bentham Science Publishers Ltd. in The Open Dermatology Journal
- Vol. 18 (1)
Open AccessSerum Visfatin Level in Psoriasis Patients: A Case-Control Study
Background: Adipokines play imperative roles in the pathogenesis of psoriasis. Among the adipokines, visfatin is attracting more attention in the clinical setting of dermatology. Objective: The study aims to evaluate the serum visfatin level in psoriasis patients compared to the non-psoriasis individuals. Material and Methods: This case-control study involved 40 psoriasis patients and 40 non-psoriasis individuals from January to October, 2023, at the Ho Chi Minh City (HCMC) Hospital of Dermato-Venereology. The diagnosis of psoriasis was based on clinical signs and symptoms. Visfatin level was spectrophotometrically measured using an Enzym-Linked Immunosorbent Assay (ELISA) kit. Afterward, data analysis was performed using SPSS version 25. Results: We recorded a significantly higher visfatin level in the psoriasis group than the controls (49.8 ± 26.04 versus 13.07 ±12.44, p-value <0.001). The cut-off threshold of visfatin level to differentiate psoriasis from non-psoriasis was 21.7 ng/ml with a sensitivity of 90% and a specificity of 85% (AUC = 0.929). We also found a positive correlation between visfatin level and Psoriasis Area and Severity Index (PASI) score (r = 0.704; p <0.001). Conclusion: Our study indicated the link between serum level of visfatin and psoriasis. Visfatin is a potential biomarker in diagnosing psoriasis and classifying the disease’s severity. In further cohort studies and clinical trials, the adipokine can be validated for its use in psoriasis.